3,191,401 Shares in Autolus Therapeutics plc (NASDAQ:AUTL) Acquired by Candriam S.C.A.

Candriam S.C.A. acquired a new position in shares of Autolus Therapeutics plc (NASDAQ:AUTL) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 3,191,401 shares of the company’s stock, valued at approximately $7,500,000. Candriam S.C.A. owned approximately 1.20% of Autolus Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of AUTL. Hennion & Walsh Asset Management Inc. acquired a new position in shares of Autolus Therapeutics during the fourth quarter valued at about $611,000. Wellington Management Group LLP lifted its holdings in Autolus Therapeutics by 35.4% in the third quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock valued at $87,919,000 after buying an additional 6,330,392 shares during the period. FMR LLC lifted its holdings in Autolus Therapeutics by 44.6% in the third quarter. FMR LLC now owns 17,773,873 shares of the company’s stock valued at $64,519,000 after buying an additional 5,478,706 shares during the period. Erste Asset Management GmbH acquired a new stake in Autolus Therapeutics in the third quarter worth $708,000. Finally, GSA Capital Partners LLP bought a new stake in shares of Autolus Therapeutics during the third quarter worth $1,082,000. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently weighed in on AUTL. Needham & Company LLC reaffirmed a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research report on Monday, January 13th. The Goldman Sachs Group upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and raised their target price for the stock from $7.00 to $7.60 in a research note on Monday, November 18th. Finally, Redburn Atlantic upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective for the company in a research note on Friday, November 15th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $10.40.

Autolus Therapeutics Stock Down 2.9 %

AUTL opened at $2.01 on Friday. Autolus Therapeutics plc has a twelve month low of $1.68 and a twelve month high of $6.63. The company has a fifty day moving average of $2.15 and a 200-day moving average of $3.08. The stock has a market cap of $534.85 million, a PE ratio of -1.66 and a beta of 2.07.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.